Skip to main content
SpringerLink
Log in

Pharmakoökonomie bei Infektionskrankheiten

  • Chapter
Die Infektiologie

  • 345 Accesses

Zusammenfassung

Angesichts immer knapper werdender Ressourcen kommen der Prävention und der adäquaten Therapie von Infektionskrankheiten eine wachsende ökonomische Bedeutung zu. Ein Ziel ist es, die Aufenthaltsdauer im Krankenhaus zu senken und auf diese Weise Kosten zu reduzieren. Da die Behandlung mit Antibiotika meistens eine kurative Therapie ist, steht nicht die Reduktion der Arzneimittelkosten, sondern eine Optimierung der Gesamttherapiekosten im Vordergrund.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 349.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 449.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bergstrom TC (1982) When is a man’s life worth more then his human capital? In: Jones-Lee MW (ed) The value of life and safety. North Holland, Amsterdam, pp 3–26

    Google Scholar 

  2. Linnerooth J (1979) The value of human life: A review of the models. Economic Inquiry 17:52–74

    Article  PubMed  CAS  Google Scholar 

  3. Avorn J (1984) Benefit and cost-analysis in geriatric care: turning age discrimination into health policy. N Engl J Med 310:1294–1300

    Article  PubMed  CAS  Google Scholar 

  4. Parsonage M (1992) Discounting and health benefits. Health Economics 1:71–76

    Article  PubMed  CAS  Google Scholar 

  5. Krahn M (1993) Discounting in the economic evaluation of health care interventions. Med Care 31/5:403–18

    Article  PubMed  CAS  Google Scholar 

  6. Leidl R (1994) A survey of the economic evaluation of early drug intervention in HIV infection. Working towards a population-based approach. In: Kaplan EH, Brandeau ML (eds) Modeling the AIDS epidemic: planning, policy and prediction. Raven Press, New York, pp 253–271

    Google Scholar 

  7. Paltiel AD, Kaplan EH (1991) Modeling Zidovudine therapy: A costeffectiveness analysis. J Acquir Immune Defic Syndr 4:795–804

    PubMed  CAS  Google Scholar 

  8. Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716–21

    Article  PubMed  CAS  Google Scholar 

  9. Detsky AS, Naglie IG (1990) A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 113:147–158

    PubMed  CAS  Google Scholar 

  10. Szucs TD (1997) Medizinische Ökonomie — Eine Einführung}. Urban&Vogel, MünchenSchramm W (1994) Die sozioökonomische Evaluation. Einführung in die Methodologie. Hämostaseologie 14:84–89

    Google Scholar 

  11. Szucs TD, Schramm W (1995) Wirtschaftlichkeitsuntersuchungen von medizinischen Therapien — Methodologische Grundlagen. Zentralbl Chir 120:577–583

    PubMed  CAS  Google Scholar 

  12. Sachverständigenrat der Konzertierten Aktion im Gesundheitswesen. Sondergutachten (1995) Krankenversicherung 2000. Nomos, Baden-Baden

    Google Scholar 

  13. Grasela TH, Paladino JA, Schentag JJ et al. (1991) Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antbiotics. Ann Pharmacother 25:857–62

    Google Scholar 

  14. Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Economics 5:1–30

    Article  CAS  Google Scholar 

  15. Von Neumann J, Morgenstern O (1953) Theory of games and economic behavior. Wiley, New York

    Google Scholar 

  16. Rosser R and Kind P (1978) A scale of valuations of states of illness: Is there a social consensus?. Int J Epidemiol 7:347–358

    Article  PubMed  CAS  Google Scholar 

  17. Kaplan R, Bush J (1982) Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol 1:61–80

    Article  Google Scholar 

  18. Vermeer F et al. (1988) Cost-benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Br Heart J 59:527–34

    Article  PubMed  CAS  Google Scholar 

  19. Torrance G, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Assoc Health Care 5:559–575

    Article  CAS  Google Scholar 

  20. Drummond M (1993) Cost-effectiveness league tables: more harm than good. Soc Sci Med 37/1:33–40

    Article  PubMed  CAS  Google Scholar 

  21. Drummond MF, Stoddard GL, Torrance GW (1987) Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford

    Google Scholar 

  22. Grossman R, Mukherjee J, Vaughan D et al. (1998) A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 113:131–141

    Article  PubMed  CAS  Google Scholar 

  23. Foran RM, Brett JL, Wulf PH (1991) Evaluating the cost impact of intravenous antibiotic dosing frequencies. Ann Pharmacoetharpy 25:546–52

    CAS  Google Scholar 

  24. Kerr JR, Barr JG, Smyth ETM, O’Hare JO (1992) Techniques for calculation of the true costs of antibiotic therapy. Eur J Clin Microbiol Infect Dis 11:823–827

    Article  PubMed  CAS  Google Scholar 

  25. Smyth ETM, Barr JB, O’Neill CA, Hogg GM (1995) An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins. Pharmacoeconomics 8/6:541–550

    Article  PubMed  CAS  Google Scholar 

  26. Emmerson AM, Lamport PA, Reeves DS (1985) The in-vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics. Curr Med Res Opin 9/7:480–493

    Article  PubMed  CAS  Google Scholar 

  27. Smith CR, Lipsky JJ, Laskin OL et al. (1980) Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 302/20:1106–9

    Article  PubMed  CAS  Google Scholar 

  28. Holloway JJ, Smith CR, Moore RD, Feroli ER Jr, Lietman PS (1984) Comparative cost effectiveness of gentamicin and tobramycin. Ann Intern Med 101:764–769

    PubMed  CAS  Google Scholar 

  29. Eisenberg JM, Koffer H, Glick HA et al. (1987) What is the cost of nephrotoxicity associated with aminoglycosides?. Ann Intern Med 107/6:900–909

    PubMed  CAS  Google Scholar 

  30. Winston DJ, Ho WG, Bruckner DA, Champlin RE (1991) Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 115:849–859

    PubMed  CAS  Google Scholar 

  31. Knaus WWE, Draper EA, Wagner DP, Zimmermann JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–828

    Article  PubMed  CAS  Google Scholar 

  32. Eleburte EA, Stoner HB (1998) The grading of sepsis. Br J Surg 70:29–31

    Article  Google Scholar 

  33. Meakins JL, Solomkin JS, Allo MD et al. (1984) A proposed classification system of intra-abdominal infections. Arch Surg 119:1372–1378

    PubMed  CAS  Google Scholar 

  34. Wacha H, Linder MM, Feldmann U et al. (1987) Mannheim peritonitis index-Prediction of risk of death from peritonitis: construction of a statistical and validation of an empirically based index. Theoret Surg 1:169–177

    Google Scholar 

  35. Teichmann W, Wittmann DH, Andreone PA (1986) Scheduled reoperations for diffuse peritonitis. Arch Surg 121:147–152

    PubMed  CAS  Google Scholar 

  36. Cooke J, Cairns CJ, Tillotsen GS et al. (1993) Comparative clinical, microbiologic, and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials. Ann Pharmacother 27:785–789

    PubMed  CAS  Google Scholar 

  37. Hillman AJW, Eisenberg JM, Pauly MV (1991) Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 324:1362–1365

    Article  PubMed  CAS  Google Scholar 

  38. Laupacis A, Feeny D, Detsky AS (1992) How attractive does a new technology have to be to warrant adoption and utilization?. Can Med Assoc J 146:473–481

    CAS  Google Scholar 

  39. Szucs T (1995) Die Grenzen der Pharmakoökonomie. In: Oberender P (eds) Kosten-Nutzen-Analysen in der Pharmakoökonomie. Gräfelfing

    Google Scholar 

  40. Udvarhelyi S, Colditz GA, Rai A, Epstein AM (1992) Cost-effectiveness and cost benefit analysis in the medical literature. Are the methods being used correctly? Ann Intern Med 116:238–244

    PubMed  CAS  Google Scholar 

  41. Henry D (1992) Economic analysis as an aid to subsidisation: the development of Australien Guidelines for Pharmaceuticals. PharmacoEconomics 1:54–67

    Article  PubMed  CAS  Google Scholar 

  42. Ontario guidelines (1994) for economic analysis of pharmaceutical products. Queens Printer for Ontario. Ontario, Canada

    Google Scholar 

  43. Guidance on Good Practice in the Conduct of Economic Evaluations of Medicines (1994) U. K. Department of Health and Association of the British Pharmaceutical Industry, May 20,’ 94

    Google Scholar 

  44. Drummond MF, Jefferson TO (1996) On behalf of the BMJ Economic Evaluation Working Party Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 313:275–283

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. medizinische Ökonomie, Universitätsspital, Postfach, 8091, Zürich, Schweiz

    Prof. Dr. T. D. Szucs

Authors
  1. Prof. Dr. T. D. Szucs
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dr. von Haunersches Kinderspital der Ludwig-Maximilians-Universität, Lindwurmstr. 4, 80337, München, Deutschland

    D. Adam

  2. Institut für Medizinische Virologie des Klinikums, Johann-Wolfgang-Goethe-Universität Frankfurt/M., Paul-Ehrlich-Str. 40, 60596, Frankfurt, Deutschland

    H. W. Doerr

  3. Westpfalz-Klinikum, Medizinische Klinik I, Hellmut Hartert Str. 1, 67653, Kaiserslautern, Deutschland

    H. Link

  4. Zentralklinik Emil von Behring Pneumologische Abteilung I, Zum Heckeshorn 33, 14109, Berlin, Deutschland

    H. Lode

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Szucs, T.D. (2004). Pharmakoökonomie bei Infektionskrankheiten. In: Adam, D., Doerr, H.W., Link, H., Lode, H. (eds) Die Infektiologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18577-9_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18577-9_42

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-00075-4

  • Online ISBN: 978-3-642-18577-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation